TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01720797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation
Description: Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthestic
Description: Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.

Intervention type: OTHER
Group type: OTHER
Intervention: Chlorhexidine
Description: Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
Study: NCT00176865

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Transplant
Description: IV on Day 0

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Transplant
Description: IV on Day 0

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem Cell Transplant
Description: IV on Day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30mg/m\^2 IV Day -7 through Day -3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30mg/m\^2 IV Day -7 through Day -3
Study: NCT02784262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botox injection Multiguide
Description: botox injection under CT/MR navigation and with the navigation tool MultiGuide
Study: NCT02183727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: L-C Ligament
Description: The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
Study: NCT00176865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 30mg/m\^2 IV Day -7 through Day -3
Study: NCT04566731

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Modified Contraint-Induced Language Therapy (mCILT)
Description: Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modified Contraint-Induced Language Therapy (mCILT)
Description: Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
Study: NCT04183517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXS-5382A
Description: Orally once daily or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXS-5382A
Description: Orally once daily or twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXS-5382A
Description: Orally once daily or twice daily
Study: NCT03207334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase~Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6.~Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients \> 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle.
Study: NCT02106039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intensive monitoring
Study: NCT03810820

Intervention type: DEVICE
Group type: OTHER
Intervention: mobile Cardiac Arrhythmia Diagnostics Service (m-CARDS)
Description: A wearable cardiac monitoring device is provided to patients pre- and post-TAVI. The monitor transmits cardiac data in real time to the m-CARDs team. Cardiac abnormalities are reported to the clinical team who then assess the abnormality and intervene as clinically necessary.
Study: NCT00176865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 140 mg/m\^2 IV Day -1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 140 mg/m\^2 IV Day -1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: 140 mg/m\^2 IV Day -1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Description: 30 mg/kg IV Day -5 through Day -1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Description: 30 mg/kg IV Day -5 through Day -1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Description: 30 mg/kg IV Day -5 through Day -1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Campath 1H
Description: 0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Campath 1H
Description: 0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Campath 1H
Description: 0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: 2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children \<40 kg) maintaining a level of \>200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: 2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children \<40 kg) maintaining a level of \>200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A
Description: 2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children \<40 kg) maintaining a level of \>200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: 15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present
Study: NCT02183727

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring Autograft
Description: The gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.
Study: NCT04982523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mental Health Program
Description: The proposed program consisted of eight sessions conducted twice per week, consisting of 5 minutes of introductory material, 12-15 minutes of main content, and 5 minutes of concluding content. The main content intended to improve the control processes and each of the four adaptive modes of the RAM. The eight sessions were uploaded on the web. Links and passwords for each session were provided to the participants through SNS. The program was accessible from any electronic device with Internet access
Study: NCT02565836

Intervention type: DRUG
Intervention: fixed-dose activated prothrombin complex concentrate
Description: FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.~Check INR after infusion and may repeat dose if INR still elevated

Intervention type: DRUG
Intervention: variable-dose inactivated prothrombin complex concentrate
Description: Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.~Check INR after infusion and may repeat dose if INR still elevated.
Study: NCT01537718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REPLY 200
Description: REPLY 200 pacemaker
Study: NCT04206462

Intervention type: OTHER
Intervention: Questionnaire of eating habits
Description: frequency and type of aliments
Study: NCT04133311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-130A
Description: Latanoprost 50 microg/ml eye drops emulsion, preservative-free eye drops emulsion in single-dose containers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xalatan®
Description: Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers.

Intervention type: DRUG
Group type: OTHER
Intervention: DE-130A/DE-130A
Description: After Week 12, received DE-130A continuously.

Intervention type: DRUG
Group type: OTHER
Intervention: Xalatan®/DE-130A
Description: From week 12 onwards, DE-130A was continued to be administered instead of Xalatan®.
Study: NCT01820962

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: when not in use CVCs are locked with heparin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: concentrated citrate
Description: when not in use the CVC is locked with concentrated citrate
Study: NCT02919462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine
Description: Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance with Metronomic Oral Vinorelbine
Description: Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance with Pemetrexed
Description: Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
Study: NCT00809705

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sc once weekly for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10mg sc once weekly for 12 weeks
Study: NCT01057368

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Day of intensive meditation practice
Description: Long-term meditators practice for \~6 hours of meditation at each time point

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: 8-week class designed to enhance well-being through training in mindfulness meditation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program (HEP)
Description: 8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
Study: NCT04034277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lee Silverman Voice Therapy
Description: LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: speech rehabilitation protocol comprehend:~* Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness.~* Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation.
Study: NCT03340545

Intervention type: OTHER
Group type: OTHER
Intervention: Custom Magnetic Resonance Elastography Device
Description: Magnetic Resonance Elastography is an imaging method to measure mechanical properties of tissues.

Intervention type: OTHER
Group type: OTHER
Intervention: Custom Magnetic Resonance Elastography Device
Description: Magnetic Resonance Elastography is an imaging method to measure mechanical properties of tissues.
Study: NCT04442503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 oral capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matched-placebo oral capsules.
Study: NCT03393754

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccination
Description: Prophylactic Hepatitis B Vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccination
Description: Prophylactic Hepatitis B Vaccination
Study: NCT01576458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ursodeoxycholic acid
Description: 450 mg/day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01816230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NiCord®
Study: NCT01167335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04083326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Patient Journey Solution
Description: Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
Study: NCT02035163

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two sites cryoablation
Description: Two ganglionic plexi around atrium was performed with 90-second cryoablation.
Study: NCT01904513

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pasteurized Whole Milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR-1
Study: NCT01567553

Intervention type: OTHER
Intervention: USPIO MRI - Gadolinium MRI
Description: USPIO MRI scanning will be performed at :~* baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.~* baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,~* baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,~* baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,~* baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.~Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36.

Intervention type: OTHER
Intervention: USPIO MRI - Gadolinium MRI
Description: USPIO MRI scanning will be performed at :~* baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.~* baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,~* baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,~* baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,~* baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.~Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36.
Study: NCT03169816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: Lorcaserin 10mg, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo for lorcaserin condition dosed twice daily
Study: NCT03828539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: 70mg/1mL (70 mg) or 2x70mg/1mL (140 mg) in pre-filled syringe, administered every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Film-coated tablet taken orally:~25 mg administered once daily (first week of titration phase). After the first week, titration was done according to the summary of product characteristics (SmPC) in 25 mg increments each week and aimed to reach the recommended daily treatment dose of 100 mg (50/75/100 mg). 50/75/100 mg were administered twice daily during titration phase and maintenance phase.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab matching placebo
Description: Erenumab matching placebo pre-filled syringue administered every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate matching placebo
Description: Topiramate matching placebo administered daily
Study: NCT01659073

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caloric Vestibular Stimulation
Study: NCT01345539

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Patients may have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy choice of agents is at the discretion of the treating medical oncologist.